B细胞非霍奇金淋巴瘤靶向药物治疗研究进展  

Advances in targeted drug therapy for B-cell non-Hodgkin's lymphoma

作　　者：马晓松 汪步海[2] 梁一晨 韩枫 吴越超 MA Xiaosong;WANG Buhai;LIANG Yichen;HAN Feng;WU Yuechao(Dalian Medical University,Liaoning Dalian 116000,China;Cancer Institute of North Jiangsu People's Hospital,Jiangsu Yangzhou 225000,China)

机构地区：[1]大连医科大学,辽宁大连116000 [2]江苏省苏北人民医院肿瘤研究所,江苏扬州225000

出　　处：《现代肿瘤医学》2022年第12期2272-2275,共4页Journal of Modern Oncology

基　　金：江苏省扬州市重点研发项目(编号:YZ2019057)。

摘　　要：B细胞非霍奇金淋巴瘤(B-cell non-Hodgkin's lymphoma,B-NHLs)代表了一组异质性的来源于血液系统的恶性肿瘤,目前针对B-NHLs一线治疗方案仍是经典标准R-CHOP方案。近几年,靶向阻断分子或细胞机制在淋巴瘤中具有改变临床实践的意义,靶向治疗手段已成为了越来越重要的预测和肿瘤治疗方案,本文就近年来B-NHLs靶向治疗新进展作一综述。B-cell non-Hodgkin lymphoma(B-NHLs)represents a group of heterogeneous malignancies derived from the blood system,and the current first-line treatment regimen for B-NHLs is still the classic standard R-CHOP regimen.In recent years,targeted blocking of molecular or cellular mechanisms has the significance of changing clinical practice in lymphoma,and targeted therapy has become an increasingly important prediction and tumor treatment regimen.This paper will review the recent progress of B-NHLs targeted therapy.

关 键 词：淋巴瘤 B细胞非霍奇金淋巴瘤 靶向治疗药物 治疗 

分 类 号：R733.4[医药卫生—肿瘤]